27 publications
Name | Date | Type | Actions |
---|---|---|---|
Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is |
15/12/2010 | Public releases | |
November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as |
30/11/2010 | Public releases | |
Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing |
18/11/2010 | Public releases | |
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
19/10/2010 | Public releases | |
Mise à disposition ou de consultation du rapport financier semestriel 2010 (french) Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur |
17/09/2010 | Public releases | |
Strong Results in the first half of 2010 The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements. |
30/08/2010 | Public releases | |
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth. |
16/07/2010 | Public releases | |
BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle. |
30/06/2010 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version) The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010. |
23/04/2010 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
Departure of Pierre Konareff April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre |
14/04/2010 | Public releases | |
2009 annual earnings March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements. |
31/03/2010 | Public releases | |
Redemption of tranche A bonds February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds. |
26/02/2010 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases | |
VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success. |
14/01/2010 | Public releases | |
Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées. |
22/12/2008 | Public releases | |
Vétoquinol strengthens its position in Europe with the acquisition of Ascor Chimici in Italy Vétoquinol announces the signing of a contract to acquire 100 percent of the shares of Ascor Chimici S.r.l, which will take effect on 1 December 2008. |
25/11/2008 | Public releases | |
Revenues for the first nine months of 2008 Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis). |
22/10/2008 | Public releases | |
Vétoquinol: 2008 results expected to be in line with objectives At its meeting of 25 August 2008, the Board of Directors of Vétoquinol S.A. reviewed the Group’s operations and approved the financial statements for |
27/08/2008 | Public releases | |
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
22/07/2008 | Public releases | |
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
08/07/2008 | Public releases | |
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
01/07/2008 | Public releases | |
Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment. |
06/05/2008 | Public releases | |
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
18/03/2008 | Public releases | |
VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe |
17/03/2008 | Public releases | |
KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french) |
25/02/2008 | Public releases | |
Revenue grows by 10.3% in 2007, to €233.4 M |
24/01/2008 | Public releases |